These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

564 related articles for article (PubMed ID: 20373018)

  • 1. Four new cases of double heterozygosity for BRCA1 and BRCA2 gene mutations: clinical, pathological, and family characteristics.
    Zuradelli M; Peissel B; Manoukian S; Zaffaroni D; Barile M; Pensotti V; Cavallari U; Masci G; Mariette F; Benski AC; Santoro A; Radice P
    Breast Cancer Res Treat; 2010 Nov; 124(1):251-8. PubMed ID: 20373018
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations.
    Satagopan JM; Boyd J; Kauff ND; Robson M; Scheuer L; Narod S; Offit K
    Clin Cancer Res; 2002 Dec; 8(12):3776-81. PubMed ID: 12473589
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Absence of genomic BRCA1 and BRCA2 rearrangements in Ashkenazi breast and ovarian cancer families.
    Stadler ZK; Saloustros E; Hansen NA; Schluger AE; Kauff ND; Offit K; Robson ME
    Breast Cancer Res Treat; 2010 Sep; 123(2):581-5. PubMed ID: 20221693
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Maternal and paternal lineage double heterozygosity alteration in familial breast cancer: a first case report.
    Pilato B; De Summa S; Danza K; Lambo R; Paradiso A; Tommasi S
    Breast Cancer Res Treat; 2010 Dec; 124(3):875-8. PubMed ID: 20730485
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of breast cancer susceptibility genes BRCA1 and BRCA2 in Thai familial and isolated early-onset breast and ovarian cancer.
    Patmasiriwat P; Bhothisuwan K; Sinilnikova OM; Chopin S; Methakijvaroon S; Badzioch M; Padungsutt P; Vattanaviboon P; Vattanasapt V; Szabo C; Saunders GF; Goldgar D; Lenoir GM
    Hum Mutat; 2002 Sep; 20(3):230. PubMed ID: 12203997
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Penetrance of breast cancer, ovarian cancer and contralateral breast cancer in BRCA1 and BRCA2 families: high cancer incidence at older age.
    van der Kolk DM; de Bock GH; Leegte BK; Schaapveld M; Mourits MJ; de Vries J; van der Hout AH; Oosterwijk JC
    Breast Cancer Res Treat; 2010 Dec; 124(3):643-51. PubMed ID: 20204502
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel BRCA1/2 mutations in Serbian breast and breast-ovarian cancer patients with hereditary predisposition.
    Dobricić J; Branković-Magić M; Filipović S; Radulović S
    Cancer Genet Cytogenet; 2010 Oct; 202(1):27-32. PubMed ID: 20804917
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BRCA1 and BRCA2 mutations in Turkish breast/ovarian families and young breast cancer patients.
    Yazici H; Bitisik O; Akisik E; Cabioglu N; Saip P; Muslumanoglu M; Glendon G; Bengisu E; Ozbilen S; Dincer M; Turkmen S; Andrulis IL; Dalay N; Ozcelik H
    Br J Cancer; 2000 Sep; 83(6):737-42. PubMed ID: 10952777
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association between clinical characteristics and risk-reduction interventions in women who underwent BRCA1 and BRCA2 testing: a single-institution study.
    Uyei A; Peterson SK; Erlichman J; Broglio K; Yekell S; Schmeler K; Lu K; Meric-Bernstam F; Amos C; Strong L; Arun B
    Cancer; 2006 Dec; 107(12):2745-51. PubMed ID: 17109443
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phenocopy breast cancer rates in Israeli BRCA1 BRCA2 mutation carrier families: is the risk increased in non-carriers?
    Bernholtz S; Laitman Y; Kaufman B; Shimon-Paluch S; Friedman E
    Breast Cancer Res Treat; 2012 Apr; 132(2):669-73. PubMed ID: 22113258
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases.
    Pal T; Permuth-Wey J; Betts JA; Krischer JP; Fiorica J; Arango H; LaPolla J; Hoffman M; Martino MA; Wakeley K; Wilbanks G; Nicosia S; Cantor A; Sutphen R
    Cancer; 2005 Dec; 104(12):2807-16. PubMed ID: 16284991
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel BRCA1 and BRCA2 germline mutations and assessment of mutation spectrum and prevalence in Italian breast and/or ovarian cancer families.
    Giannini G; Capalbo C; Ristori E; Ricevuto E; Sidoni T; Buffone A; Cortesi E; Marchetti P; Scambia G; Tomao S; Rinaldi C; Zani M; Ferraro S; Frati L; Screpanti I; Gulino A
    Breast Cancer Res Treat; 2006 Nov; 100(1):83-91. PubMed ID: 16847550
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations.
    Casey MJ; Synder C; Bewtra C; Narod SA; Watson P; Lynch HT
    Gynecol Oncol; 2005 May; 97(2):457-67. PubMed ID: 15863145
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of ten novel and 13 recurring BRCA1 and BRCA2 germline mutations in Italian breast and/or ovarian carcinoma patients. Mutations in brief no. 178. Online.
    De Benedetti VM; Radice P; Pasini B; Stagi L; Pensotti V; Mondini P; Manoukian S; Conti A; Spatti G; Rilke F; Pierotti MA
    Hum Mutat; 1998; 12(3):215. PubMed ID: 10660329
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate.
    Piver MS
    Oncologist; 1996; 1(5):326-330. PubMed ID: 10388011
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BRCA1 and BRCA2 mutation status and tumor characteristics in male breast cancer: a population-based study in Italy.
    Ottini L; Masala G; D'Amico C; Mancini B; Saieva C; Aceto G; Gestri D; Vezzosi V; Falchetti M; De Marco M; Paglierani M; Cama A; Bianchi S; Mariani-Costantini R; Palli D
    Cancer Res; 2003 Jan; 63(2):342-7. PubMed ID: 12543786
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characteristics of double heterozygosity for BRCA1 and BRCA2 germline mutations in Korean breast cancer patients.
    Noh JM; Choi DH; Nam SJ; Lee JE; Kim JW; Kim SW; Kang E; Lee MH; Ahn SH; Kim KS; Park SK; Haffty BG;
    Breast Cancer Res Treat; 2012 Jan; 131(1):217-22. PubMed ID: 21847643
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel germline BRCA1 and BRCA2 mutations in Turkish women with breast and/or ovarian cancer and their relatives.
    Egeli U; Cecener G; Tunca B; Tasdelen I
    Cancer Invest; 2006; 24(5):484-91. PubMed ID: 16939956
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Breast cancer risks in individuals testing negative for a known family mutation in BRCA1 or BRCA2.
    Domchek SM; Gaudet MM; Stopfer JE; Fleischaut MH; Powers J; Kauff N; Offit K; Nathanson KL; Robson M
    Breast Cancer Res Treat; 2010 Jan; 119(2):409-14. PubMed ID: 19885732
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Histology of prophylactically removed ovaries from BRCA1 and BRCA2 mutation carriers compared with noncarriers in hereditary breast ovarian cancer syndrome kindreds.
    Casey MJ; Bewtra C; Hoehne LL; Tatpati AD; Lynch HT; Watson P
    Gynecol Oncol; 2000 Sep; 78(3 Pt 1):278-87. PubMed ID: 10985881
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.